Hua Medicine-B (02552) experienced a significant surge of over 14% during the morning trading session. At the time of reporting, the stock had risen by 14.15%, reaching a price of HK$3.55, with a turnover of HK$17.6108 million.

The company announced its performance projections for the 2025 fiscal year. During the reporting period, the commercialization of its core product, HuaTangNing® (dorzagliatin tablets) - a global first-in-class new drug for diabetes and a glucokinase activator (GKA) - is expected to accelerate significantly. The research and development pipeline will continue to expand, and financial performance is projected to achieve a historic breakthrough, successfully entering a new phase of profitability. For the period, product sales volume is forecast to reach 4.011 million boxes, representing a year-on-year increase of 91%. Net sales are anticipated to hit 492.9 million yuan, a 93% increase compared to the previous year.

The company is projected to achieve record profitability in 2025, with pre-tax profit expected to reach 1.1064 billion yuan. The cash balance remains robust, projected to stand at 1.0923 billion yuan by the end of the year, laying a solid foundation for continued operational development. The gross profit margin is forecast to improve to 56.9%, while the ratio of selling expenses is expected to be optimized from 59.9% to 33.6%, indicating a significant enhancement in profitability.